Related Experiment Video
Updated: May 7, 2026

Genetic Analysis of Hereditary Transthyretin Ala97Ser Related Amyloidosis
Published on: June 9, 2018
Wild-type transthyretin cardiac amyloidosis mimicking hypertrophic obstructive cardiomyopathy : A case report
Nikol Kubinova1, Tomas Paleček2, Marek Mika3
12nd Department of Medicine-Department of Cardiovascular Medicine, First Faculty of Medicine, Charles University in Prague and General University Hospital in Prague, U Nemocnice 2, 128 08 Prague 2, Czech Republic.
Insights
Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) can present atypically, even with dynamic left ventricular outflow tract obstruction. Endomyocardial biopsy confirmed ATTRwt CA in a patient with suspected hypertrophic cardiomyopathy.
Area of Science:
- Cardiology
- Cardiovascular Imaging
- Amyloidosis Research
Background:
- Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) is an emerging cause of heart failure in older adults.
- Clinical presentation of ATTRwt CA can be atypical, complicating diagnosis.
- A 65-year-old man presented with acute coronary syndrome and left ventricular thickening.
Purpose of the Study:
- To investigate a challenging case of suspected cardiac amyloidosis.
- To highlight atypical presentations of ATTRwt CA.
- To emphasize the role of endomyocardial biopsy in diagnosis.
Main Methods:
- Echocardiography revealed diffuse left ventricular thickening and dynamic outflow tract obstruction.
- Patient history included carpal tunnel syndrome and polyneuropathy.
- Diphosphonate scintigraphy was suggestive of ATTRwt CA; genetic testing for HCM was negative.
- Endomyocardial biopsy was performed for definitive diagnosis.
Main Results:
- Echocardiography showed diffuse concentric left ventricular thickening.
- Systolic anterior motion of the mitral valve caused dynamic LV outflow tract obstruction.
- Biopsy confirmed wild-type transthyretin cardiac amyloidosis.
Conclusions:
- Dynamic LV outflow tract obstruction is rare in cardiac amyloidosis but can mimic hypertrophic cardiomyopathy.
- Clinical 'red flags' should prompt consideration of ATTRwt CA in cases of LV wall thickening.
- While noninvasive methods are improving, endomyocardial biopsy remains crucial for ambiguous cases of ATTRwt CA.
Background:
Wild-type transthyretin cardiac amyloidosis (ATTRwt CA) is increasingly recognized as an important cause of heart failure and arrhythmias in older people. There are several clinical, echocardiographic, electrocardiographic (ECG) and laboratory features that increase the suspicion for ATTRwt CA. Presentation and phenotype can, however, be associated with atypical findings making it difficult to make a correct diagnosis. A 65-year-old man was admitted for an acute coronary syndrome. Echocardiography revealed diffuse concentric left ventricular (LV) thickening. Because of a history of bilateral carpal tunnel syndrome and polyneuropathy, the patient underwent dedicated laboratory testing and diphosphonate scintigraphy the results of which were suggestive of transthyretin cardiac amyloidosis. Also, a dynamic LV outflow tract obstruction due to the systolic anterior motion of the anterior mitral valve was noted on echocardiography during the initial investigations. Genetic testing for hypertrophic cardiomyopathy was negative. Seeking a conclusive diagnosis, endomyocardial biopsy was performed. This confirmed the diagnosis of ATTRwt CA.
Discussion:
The presence of dynamic LV outflow tract obstruction is typically seen in patients with sarcomeric hypertrophic cardiomyopathy. It can be rarely seen also in individuals with cardiac amyloidosis, including ATTR-wt CA. The presence of so-called red flags in patients' history, physical examination, laboratory test, ECG and imaging should raise suspicion for other etiologies of LV wall thickening than hypertrophic cardiomyopathy. Although noninvasive diagnosis of ATTRwt CA is possible in most patients, endomyocardial biopsy remains necessary in cases with diagnostic ambiguity.
Related Concept Videos
Cardiomyopathy I: Introduction and Classification
Cardiomyopathy II: Dilated Cardiomyopathy
Cardiomyopathy III: Hypertrophic Cardiomyopathy
Cardiomyopathy IV: Restrictive Cardiomyopathy
Cardiomyopathy V: Interprofessional Care
